Instruction: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
- -----------------------------------ATTENTION------------------------------------
INTENTIONAL MISTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL
VIOLATIONS (SEE 18 U.S.C. 1001).
- --------------------------------------------------------------------------------
<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25 SEC FILE NUMBER
0-28128
NOTIFICATION OF LATE FILING ---------------
CUSIP NUMBER
286171103
(Check One): |_|Form 10-K |_|Form 20-F |_|Form 11-K |X|Form 10-Q |_|Form N-SAR
For Period Ended:
( ) Transition Report on Form 10-K
( ) Transition Report on Form 20-F
( ) Transition Report on Form 11-K
( X ) Transition Report on Form 10-Q
( ) Transition Report on Form N-SAR
For the Transition Period Ended: December 31, 1999
--------------------------------------
-------------------------------------------------------------
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION
HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.
-------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- --------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
Biorelease Corp.
- --------------------------------------------------------------------------------
Full Name of Registrants:
- --------------------------------------------------------------------------------
Former Name if Applicable
340 Granite Street, Suite 200
- --------------------------------------------------------------------------------
Address of Principal Executive Offices (Street and Number)
Manchester, NH 03102-4004
- --------------------------------------------------------------------------------
City, State and Zip Code
<PAGE>
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed (Check box if appropriate)
_
|_| (a) The reasons described in reasonable detail in Part III
of this form could not be eliminated without
unreasonable effort or expense;
X (b) The subject quarterly report on Form 10-Q will be filed
on or before the fifth calendar day following the
_ prescribed due date; and
|_| (c) The accountant's statement or other exhibit required by
Rule 12(b)-25(c) has been attached if applicable.
PART III -- NARRATIVE
State below in reasonable detail the reasons why the Form 10-Q could not be
filed within the prescribed time period. (Attach Extra Sheets If Needed)
"The Company's audit firm requires additional time to review the quarterly
financial statement for compliance before filing."
PART IV --OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification:
R. Bruce Reeves 603 641-8443
------------------------------------------------------------- --- --------
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months (or for such shorter) period that
the registrant was required to file such reports) been filed? If answer is
no, identify report(s). _
X Yes |_| No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? _
|_| Yes X No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
Biorelease Corp.
-------------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on their behalf by the undersigned
hereunto duly authorized.
Date February 15, 1999 By /s/ R. Bruce Reeves
--------------------------- ---------------------------------------
R. Bruce Reeves, President
